| Management domain | Real-world implementation | Key details / quantitative data | Evidence / outcomes | Citations |
|---|---|---|---|---|
| Acute liver crisis management | Supportive, emergency-focused inpatient care during febrile-triggered cholestatic/ALF episodes | Reported measures include infection control, IV N-acetylcysteine (example dose 100 mg/kg/day in one report), correction of coagulopathy with fresh frozen plasma/platelets, antibiotics when indicated, ursodeoxycholic acid, fat-soluble vitamin supplementation, lactulose as needed, and close monitoring of bilirubin, INR, transaminases, glucose, ammonia, and encephalopathy | Most liver crises can recover with supportive treatment, but fibrosis may accumulate over time; crises are commonly triggered by febrile illnesses/intercurrent infections | (pqac-00000000, pqac-00000002, pqac-00000003, pqac-00000004, pqac-00000007, pqac-00000034) |
| Chronic hepatic monitoring | Longitudinal hepatology follow-up between crises | Serial liver biochemistry and synthetic function monitoring; nutritional optimization; cholestasis/pruritus management; surveillance for fibrosis/cirrhosis; monitoring for hepatosplenomegaly and growth failure | Lenz et al. reported fibrosis in all 7/7 patients despite transient crises; later reports emphasize chronic surveillance because apparent inter-episodic recovery does not exclude progression | (pqac-00000000, pqac-00000006, pqac-00000007) |
| Neurologic monitoring | Serial neurology assessment and imaging | Ongoing assessment for gait decline, tremor, peripheral neuropathy, speech/language delay, cerebellar ataxia/atrophy; repeat brain MRI may be needed because early imaging can be nondiagnostic | Neurologic progression may continue even when hepatic disease stabilizes or after liver transplantation | (pqac-00000006, pqac-00000008, pqac-00000030, pqac-00000033) |
| Liver transplantation | Used for progressive/recurrent liver failure not controlled by supportive care | In the foundational cohort, 1 child underwent transplant at 23 months; by 2023 literature review, 3 prior CALFAN patients had undergone transplant in infancy/early childhood at 7, 21, and 23 months; Youssef et al. added a transplant in adulthood at age 20 years | Adult-transplanted patient was doing well at 3-year follow-up; no acute cellular rejection reported; prior transplanted cases reportedly had no graft failure with 8-11 years follow-up; neurologic deficits may persist/progress despite hepatic stabilization | (pqac-00000000, pqac-00000008, pqac-00000009, pqac-00000010) |
| Post-transplant expectations | Hepatic benefit but incomplete extrahepatic rescue | Adult case most recent labs after transplant: TB 2.1 mg/dL, direct bilirubin 0.4 mg/dL, ALP 72 IU/L, ALT 18 IU/L, AST 13 IU/L, GGT 4 U/L; persistent cerebellar atrophy, leg-brace use, and limited expressive language remained | Supports transplant as liver-directed therapy rather than cure of neurodegeneration | (pqac-00000008, pqac-00000010) |
| Rehabilitation / physiotherapy (published case report) | Individualized 12-week physical therapy program | 45-minute sessions, 3 days/week; trunk stabilization, balance training, functional exercises, Swiss-ball and perturbation-based training, scoliosis brace/orthosis support, thoracic expansion and diaphragmatic breathing exercises | Quantitative changes: ICARS 47→42; TIS 9→13; WeeFIM 79→83; PedsQL 47.11→52.17; Q-DASH 59→56; 9-HPT right 48.8s→42.9s, left 66.1s→56.4s; thoracic Cobb 34°→36°, lumbar Cobb 32°→21° | (pqac-00000025, pqac-00000026, pqac-00000028, pqac-00000029) |
| Rehabilitation / physiotherapy (registered study) | Prospective single-case interventional rehabilitation study | ClinicalTrials.gov NCT04653909; single-group, enrollment=1; start 2020-03-01, primary completion 2020-10-20, study completion 2020-11-17; intervention included abdominal/back strengthening, perturbation training in sitting/standing, functional ADL-simulating exercises, scoliosis stretching/strengthening, and trunk orthoses | Primary outcomes: TIS, ICARS, PedsQL, WeeFIM; secondary: 9-Hole Peg Test and Q-DASH; record describes CALFAN as ultra-rare with ~11 reported patients at time of registration | (pqac-00000035) |
| Diagnostic implementation in acute care | Early exome/genomic testing to clarify etiology of indeterminate pediatric ALF / low-GGT cholestasis | Whole-exome sequencing repeatedly enabled diagnosis in reported patients, including urgent-care contexts and cases considered for transplant; suggested especially when fever-triggered recurrent ALF occurs with neurologic signs or consanguinity/family history | Rapid molecular diagnosis informs prognosis, recurrence risk, and transplant decision-making | (pqac-00000031, pqac-00000033, pqac-00000034) |
| Genetic counseling / prevention | Family counseling, cascade testing, reproductive planning | Autosomal recessive inheritance; recurrence-risk counseling recommended; prenatal and preimplantation genetic testing options noted in recent review/case literature; family history of unexplained infantile liver failure is an important clue | No primary prevention for the genetic disorder itself; practical prevention focuses on anticipatory guidance, early evaluation of febrile illnesses, and reproductive counseling for at-risk families | (pqac-00000001, pqac-00000007, pqac-00000031) |
| Tertiary prevention / complication reduction | Avoidance of hepatotoxic stressors and prompt treatment of intercurrent infections | Suggested measures include early treatment/prevention of infections, hydration/nutritional support during illness, avoidance of hepatotoxic drugs, and multidisciplinary follow-up (hepatology, neurology, genetics, rehabilitation) | Intended to reduce severity of recurrent decompensation and preserve function/QoL, though controlled evidence is lacking because of extreme rarity | (pqac-00000003, pqac-00000004, pqac-00000007, pqac-00000037) |


*Table: This table summarizes current real-world management approaches reported for CALFAN syndrome, including acute liver crisis care, chronic surveillance, transplantation, rehabilitation, and genetic counseling. It also captures the limited quantitative outcome data available from case reports and the single registered rehabilitation study.*